伊顿制药 (ETON) 2026财年第二季度业绩电话会：营收增长99%，上调业绩指引

核心要点

• 2026财年第二季度营收同比增长99%，达到创纪录的3760万美元，这主要得益于Hemangiol的重新上市，以及Increlex、肾上腺素系列产品、Galzin和卡谷氨酸（carglumic acid）的增长。
• 调整后EBITDA从2025财年第二季度的310万美元（占营收的16%）增至1620万美元（占营收的43%）。GAAP净利润达到1160万美元，即摊薄后每股收益0.35美元。
• 管理层将2026财年全年营收指引从超过1.20亿美元上调至超过1.45亿美元。预计调整后EBITDA利润率从30%以上上调至35%以上。
• 自5月1日重新上市以来，Hemangiol已成为Eton最大的产品。截至6月底，约95%的患者已过渡至Eton Cares服务，管理层表示该过渡现已完成。
• Eton获得了ASN001的许可，这是一种用于治疗婴儿血管瘤的后期外用候选药物。公司计划开展一项包含24名患者的生物利用度研究，并预计在2027年下半年提交新药申请（NDA），有望支持其在2028年上市。
• 在提前偿还300万美元债务后，Eton在本季度末拥有2680万美元现金。公司计划在未来6至12个月内，优先考虑增值型产品收购，同时加速偿还剩余的信贷额度。

主要财务数据

业务与经营业绩

Hemangiol与儿科皮肤科

Hemangiol是季度增长的最大贡献者，并成为Eton最大的产品。公司过往估计每年约有8000名患者接受治疗。管理层继续预计整个疗程的平均净实现价格为8000至10000美元，不过每月的结果可能会因支付方和患者结构的不同而有所差异。

随着药房过渡工作基本完成，Eton正专注于提高目前接受成人在标外（off-label）剂型治疗的患者中的采用率。管理层表示，Hemangiol的年患者人数最终应超过10000人。

ASN001旨在补充Hemangiol，用于治疗中度婴儿血管瘤。管理层估计，将这两种产品结合使用可将Eton的每年目标患者群体扩大到约20000至30000人。计划开展的为期29天、包含24名患者的生物利用度研究预计在未来12个月内耗资约400万美元。

儿科内分泌学

Alkindi Sprinkle和KendiV肾上腺素系列产品的活跃患者数已突破600人。Eton提交了事先批准补充申请（PAS），寻求将KendiV的适用人群扩展至5岁以下患者，管理层预计将于2027年上半年获得决定。

Desmoda完成了上市后的首个完整季度。管理层表示，新增患者人数约为目标的115%，尽管该产品尚未对第二季度增长做出重大贡献。

Increlex实现强劲的同比营收增长。FDA已同意标签协调研究方案，Eton的目标是在今年年底前完成首例患者给药。

Amglidia获得了FDA的快速通道资格认定。Eton正在启动一项生物利用度研究，并计划在2026年底前提交新药申请（NDA），可能于2027年获得批准并上市。

肝豆状核变性（威尔逊氏病）及其他罕见病

随着Eton将患者从非处方锌制剂转化为其产品使用者，Galzin保持继续增长。管理层估计，通过锌疗法治疗的患者中只有不到一半得到了转化。

包含36名志愿者的ET-700试点研究正在使用PET扫描评估肠道铜吸收情况，对Galzin、ET-700和安慰剂进行比较。初始结果预计将在1至2个月内公布，完整报告将于年底前出炉。成功的成果可能会支持在2027年初开展关键性研究。

Eton计划于9月下旬开始在美国分销Impavido。管理层预计该产品每年将贡献数百万美元的收入，不过由于其利润分成结构，其利润率将低于组合中的某些其他产品。

管理层业绩指引

研发展望包含300万美元的ASN001预付许可费，预计将在2026财年第三季度计入费用。调整后毛利率指引包含与Alkindi Sprinkle和KendiV净销售额门槛挂钩的潜在第四季度商业里程碑付款。

管理层表示，Eton在实现到2027年底年化营收运行率达到2亿美元的目标方面提前于计划。公司还保持了在2028年实现50%调整后EBITDA利润率的目标，并表示ASN001支持其到2030年年营收至少达到5亿美元的目标。

风险与关注领域

• 调整后毛利率从75%降至73%，主要是因为美国境外较高的Increlex销售产生了负毛利率。
• Hemangiol的实际净价格可能会因患者结构、过渡期供应（bridge supply）和支付方结构而波动，尤其是在分销过渡之后。
• 一名分析师强调了Hemangiol专利将于2028年10月到期的情况。Eton正在评估可能增加知识产权的配方改进方案，但未提供具体的成果或时间表。
• ASN001、Amglidia、ET-700和Increlex标签扩展仍取决于临床、监管和申报里程碑。
• 截至6月30日，Eton维持了对递延所得税资产约2200万美元的估值准备（valuation allowance）。未来的冲回可能会带来重大的单次非现金GAAP税收收益。

分析师问答精选

• 管理层拒绝透露单一产品的营收贡献，但重申在患者过渡完成后，Hemangiol具有巨大的增长潜力。
• ASN001预计将利用现有的儿科皮肤科销售团队和客户关系。管理层将生物利用度研究描述为申报前唯一需要完成的剩余研究。
• Eton目前没有扩大其内分泌科销售团队的计划，理由是整个产品组合的相关处方医生重叠度超过90%。
• 对于Impavido，Eton计划引入外勤销售覆盖、集中式Eton Cares服务、0美元自付额支持以及医疗补助（Medicaid）覆盖。目标市场包括约300家集中的传染病诊所账户。

业绩电话会议完整实录

完整财报电话会议逐字稿

管理层陈述

Operator

Thank you. Good afternoon, and welcome to the Eton Pharmaceuticals Second Quarter 2026 Financial Results Conference Call. [Operator Instructions] Please be advised this call is being recorded at the company's request. At this time, I'd like to turn the call over to David Krempa, Chief Business Officer at Eton Pharmaceuticals. Please proceed.

David Krempa

Thank you, operator. Good afternoon, everyone, and welcome to Eton's second quarter 2026 conference call. This afternoon, we issued a press release that outlines the topics we plan to discuss on today's call. The release is available on our website, etonpharma.com. Joining me on our call today, we have Sean Brynjolfsson, CEO; Ipek Erincin, our Chief Commercial Officer; and [ Judy Matthews ], our Chief Financial Officer. Before we begin, I would like to remind everyone that today's remarks made during the call may contain forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially from those contained in these forward-looking statements. Please see the forward-looking statements disclaimer in our earnings release and the risk factors in the company's filings with the SEC. Now, I will turn the call over to our CEO, Sean Brynjolfsson.

Sean Brynjolfsson

Thank you, David. Good afternoon, everyone, and thank you for joining us today. We had an exceptional second quarter with record revenue, significant margin expansion, and important progress across both our commercial portfolio and pipeline. We also completed several strategic transactions that we believe will support Eton's continued long-term growth. I'll begin by highlighting a few of the quarter's key accomplishments. We once again achieved record revenue, delivering 99% year-over-year growth with contributions from across the portfolio. At the same time, we delivered significant margin expansion and accelerated adjusted EBITDA and net income growth.

We established a strong commercial foundation in pediatric dermatology with the successful relaunch of Hemangiol, which is already performing ahead of our expectations. We expanded our portfolio through the acquisition of U.S. rights to Impavido and the licensing of ASN001, adding both a commercial rare disease product and a late-stage development candidate that we believe has the potential to become the largest product in our portfolio. And finally, we had a very productive few months on the R&D front. We submitted a PAS, Prior Approval Supplement, for the [ KendiV ] label expansion, initiated the ET-700 pilot study, began preparations for the Increlex label harmonization study, and also received Fast Track designation for Amglidia.

Starting with the financials, it was another record quarter for Eton. Revenue reached $37.6 million, an increase of 99% year over year. Hemangiol had an exceptional relaunch quarter and was the largest contributor to our growth. But importantly, the strength was broad-based with continued momentum across our pediatric endocrinology franchise and Galzin. Based on our strong second quarter performance and favorable outlook for the remainder of the year, we are once again raising our 2026 revenue guidance. We expect full-year revenue to exceed $145 million, up from our previous guidance of more than $120 million. Profitability has always been a core focus at Eton, and that was apparent in our results this quarter. Adjusted EBITDA increased to $16.2 million, or 43% of revenue, compared with $3.6 million, or 16% of revenue, in the prior year quarter.

Even after new incremental expenses related to the ASN001 transaction, which I will discuss in detail shortly, we now expect our full-year adjusted EBITDA margin to exceed 35%, up from our prior guidance of greater than 30%. For the last several years, we've talked about the scalability and operating leverage inherent in our model. We're now seeing that play out in the financial results. As we continue to grow revenue, we expect an increasing proportion of that growth to translate into earnings. Longer term, we continue to believe this business can generate an adjusted EBITDA margin above 50%.

Turning to our product portfolio, I'll start with pediatric dermatology, which has quickly become an important new franchise for Eton. We relaunched Hemangiol as planned on May 1, and the product is performing ahead of our expectations. Historically, approximately 8,000 patients annually were treated with Hemangiol, and the patients accessed the product through 18 different pharmacies. When we acquired Hemangiol, we saw a significant opportunity to streamline and improve that experience by moving patients to a single, high-touch access model through Eton Cares, reducing patient out-of-pocket costs, accelerating access to medication, and providing 24/7 patient support. Transitioning an entire patient population to a new distribution model was a significant operational undertaking, particularly given the nature of infantile hemangioma treatment, where therapy typically lasts only about 6 months.

We weren't simply transitioning a static patient population. We were simultaneously converting existing patients, onboarding newly diagnosed infants, and supporting patients completing therapy, all while introducing physicians and their office staff to an entirely new access and fulfillment model. We originally expected that transition to take 3 to 4 months. I'm very proud of our team's execution. By the end of June, we estimate that approximately 95% of patients had transitioned to the new model well ahead of our expectations. Critically, this was accomplished while maintaining continuity of care for patients and their families. Today, every Hemangiol patient has access to the full Eton Cares patient support program. Previously, many families were paying approximately $55 per bottle, which in some cases could total more than $100 per month.

Our goal is simple. Families dealing with infantile hemangiomas shouldn't also have to worry about whether they can afford the medication their child needs. With the transition of existing patients largely behind us, our commercial attention is now shifting to the broader opportunity, helping ensure that more infants from whom Hemangiol is appropriate receive a therapy specifically developed and approved for infantile hemangioma, instead of relying on off-label adult formulations. Those off-label products were not developed for infantile hemangioma and contained excipients such as alcohol, sugar, and other ingredients that are not appropriate for infants. In our conversations with physicians, we've consistently heard that the historical out-of-pocket cost of Hemangiol was 1 factor contributing to off-label prescribing. With Eton Cares and our $0 copay program now in place, we believe we've removed an important barrier to broader adoption and are well positioned to drive continued growth.

We are extremely pleased with the Hemangiol acquisition. It has quickly become our largest product and established Eton as a leader in the infantile hemangioma space. But as we've spent more time with pediatric dermatologists, vascular anomaly specialists, and families, it's become clear that Hemangiol addresses only part of the treatment landscape. For severe hemangiomas requiring treatment, Hemangiol is the established standard of care, and we estimate that population to be approximately 10,000 to 15,000 patients annually. But infantile hemangiomas affect more than 100,000 patients annually in the United States and exist across a broad spectrum of severity. This means that a significant number of infants with moderate infantile hemangiomas, we estimate 10,000 annually, are being treated off-label with ophthalmic timolol because there simply isn't an FDA-approved topical therapy available.

These timolol ophthalmic products were developed for glaucoma, not infantile hemangiomas, and present a number of practical limitations, including variable dosing, formulation challenges, the absence of FDA-approved labeling, and reimbursement limitations. To us, that represented both a clear unmet need, and we saw firsthand the evidence that physicians and families are looking for a better option. That is what ultimately led us to ASN001, which was specifically developed for infantile hemangiomas and is supported by clinical data. There are several reasons we're particularly excited about ASN001. First, the potential patient population could be 2 to 3 times larger than Hemangiol. Second, ASN001 is expected to be prescribed by the same healthcare professionals as Hemangiol, allowing us to leverage our existing commercial infrastructure and strong relationships we've already been building with thought leaders and vascular anomaly centers. And third, as a new product launch, ASN001 would not be subject to certain rebate dynamics that weigh on Hemangiol's gross-to-net.

As a result, we believe ASN001 will likely have more favorable net pricing economics for Eton. Put those factors together and we believe ASN001 has a clear path to becoming the largest product in our portfolio. And to be clear, we expect ASN001 to complement Hemangiol rather than compete with it. The 2 products address different segments of the disease spectrum and together would allow Eton to support physicians treating infantile hemangiomas across a much broader range of patients. With ASN001 in our portfolio, we believe the addressable market could expand to approximately 20,000 to 30,000 patients annually. From a development standpoint, ASN001 has already completed a Phase 3 trial that showed compelling efficacy compared with placebo. Our final remaining development requirement is a bioavailability bridging study, which we plan to initiate in the coming weeks.

The proposed study protocol has been reviewed by the FDA and consists of a 24-patient, 29-day study assessing the pharmacokinetics of ASN001. We expect that study to cost approximately $4 million over the next 12 months. Following completion of the study, we expect to be ready to submit the NDA in the second half of 2027, allowing for a potential approval and launch in 2028. We believe the ASN001 transaction, together with the Hemangiol acquisition earlier this year, demonstrates 2 defining aspects of Eton's strategy and capabilities. First is our ability to identify and execute highly strategic, potentially transformational transactions. At the end of 2024, Increlex represented a transformational acquisition and became our largest product. Now, in just the last 6 months, we have acquired and successfully integrated what has become our largest revenue-generating product, while also adding what we believe is now our highest-value pipeline program, and we've accomplished both without external financing and while expanding profitability.

We believe that combination demonstrates the strength of our business model and our disciplined approach to capital allocation. We will continue pursuing commercial and development stage transactions that we believe can accelerate revenue and earnings growth and create significant long-term value for shareholders. The second defining capability is what we believe to be 1 of Eton's greatest competitive advantages, our ability to thoughtfully enter new therapeutic areas and rapidly build leadership positions by leveraging the commercial capabilities we've already established. Pediatric dermatology is a great example. We entered the market with Hemangiol on May 1. Just 90 days later, we expanded that franchise with ASN001, a product that can leverage the same commercial organization, customer relationships, and foundational infrastructure.

We've successfully executed this playbook before. We entered pediatric endocrinology with Alkindi Sprinkle and then expanded that platform with 3 additional high-value commercial products in the specialty. Similarly, we entered metabolics with carglumic acid and subsequently expanded the platform through additional transactions. Importantly, we've been able to build these franchises while continuing to grow our existing portfolio and maintaining discipline around operating expenses. We've proven this is a repeatable strategy and 1 that Eton is particularly well positioned to execute. We expect to enter a number of new specialties in the coming years. Ultimately, our mission is simple: bring as many important rare disease therapies to patients as possible.

Beyond infantile hemangioma, we've had a number of important developments across our commercial and development stage products. We won't have time to cover all of them this afternoon, but I'll highlight several of the most significant. And I'll start with our high-performing pediatric endocrinology portfolio. Our adrenal franchise of Alkindi Sprinkle and [ KendiV ] continues to deliver the reliable, steady growth we've seen for more than 5 years, now exceeding 600 active patients and continuing to grow. Last week, we announced that our new [ KendiV ] formulation successfully demonstrated bioequivalence to the reference product Alkindi Sprinkle. As a result, we were able to submit our prior approval supplement, requesting approval of a broader age range. [ KendiV ] is currently approved for patients 5 years of age and older. We continue to believe expanding the label to include patients under 5 would be an important catalyst for broader adoption and accelerate our path toward our goal of 1,000 active patients. We expect the expanded label to be approved in the first half of 2027.

We also launched [ Desmoda ] at the end of the first quarter and have been very encouraged by the early response from the endocrinology community who are glad to have the option of an oral liquid desmopressin solution to enable individualized dosing. Desmopressin dosing can vary significantly from patient to patient and often requires multiple dose adjustments throughout the treatment journey. [ Desmoda ] was specifically designed to address that need through precise, flexible dosing, and that differentiation is resonating strongly with clinicians. Beyond the launch itself, [ Desmoda ] is also helping us establish relationships with adult endocrinologists, expanding our commercial reach beyond our traditional pediatric call point. We are continuing to invest in peer-to-peer education, engage key opinion leaders, and build awareness through national and regional medical meetings, which include a strong presence at the Endocrine Society Annual Meeting in June. These activities are supporting the [ Desmoda ] launch while also strengthening our broader endocrinology platform and creating opportunities across Alkindi Sprinkle, [ KendiV ], and Increlex.

Increlex also delivered strong year-over-year revenue growth during the quarter, and we continue to advance our label harmonization study, which we believe could substantially expand the product's long-term market opportunity. FDA has signed off on our study protocol and we have executed an agreement with a leading CRO to initiate the study. Our team is now actively engaged in study startup activities with the goal of dosing the first patient by the end of the year. Rounding out our pediatric endocrinology portfolio is Amglidia. We recently received Fast Track designation from the FDA, which is designated or designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. Amglidia is a liquid glyburide product used to treat neonatal diabetes, an extremely rare condition infecting only a few hundred children in the United States.

While the product is approved and widely used in Europe, there is currently no approved oral treatment for neonatal diabetes in the United States. We are initiating the product's bioavailability study this month and plan to submit the NDA by the end of the year, allowing for potential approval and launch in 2027. Given the Fast Track designation, we intend to request priority review with our NDA submission. Now, moving on to our Wilson Disease franchise. Galzin once again delivered strong revenue growth during the quarter as we continue to convert patients who have historically relied on over-the-counter zinc products. Despite the progress we've made since the relaunch, we believe we have converted less than half of the patients currently managed with zinc therapy. That leaves a substantial opportunity for continued growth.

We're continuing to strengthen the franchise through our strategic partnership with the Wilson Disease Association, deeper engagement with leading centers of excellence, and expanded participation at hepatology congresses. Combined with the differentiated support offered through Eton Cares, we believe these investments position Galzin well ahead for sustained growth. Longer term, we see an opportunity to further expand our Wilson disease franchise with ET-700, our proprietary patent-pending extended release formulation of zinc acetate. Our pilot study is currently ongoing. It is a double-blind placebo-controlled clinical trial involving 36 healthy volunteers. The study will use PET scans with radioactive tracer copper to compare the effects of Galzin, ET-700, and placebo on intestinal copper absorption. We expect initial results in the next month or 2 with the full study report expected by the end of the year.

If successful, the pilot study would support the initiation of a pivotal clinical study in early 2027. If ultimately approved, we believe ET-700 could potentially exceed $100 million in peak annual U.S. sales. Lastly, I'll finish the portfolio discussion with another recent addition, Impavido. Impavido is the only FDA-approved oral therapy for severe forms of leishmaniasis, a rare but potentially life-threatening parasitic disease that can cause severe skin lesions, disfiguring mucosal disease, or life-threatening visceral infection. As a life-saving treatment for an ultra-rare condition, Impavido was a strong strategic fit for Eton, and we believe patients will benefit from expanded access through our Eton Cares program. Eton will also begin distributing the product in the U.S. in late September, and we expect Impavido to be another strong addition to our growing portfolio of orphan therapies.

At the beginning of this year, we laid out 3 ambitious long-term goals for Eton. First, to exit 2027 at a $200 million annualized revenue run rate. We now believe that Eton is well ahead of this goal. Second, to achieve a 50% adjusted EBITDA margin in 2028. As noted, we have already exceeded 40% in the second quarter this year. And third, to reach $500 million in annual revenue by 2030. With the addition of ASN001, Eton expects to achieve or exceed this goal. Following our first half performance, the successful Hemangiol relaunch, the addition of ASN001, and the continued strength of our broader portfolio, we believe we are well positioned to sustain momentum into the future.

Just as importantly, our recent success has put Eton in an even stronger position to continue pursuing value-creating business development opportunities. Our commercial track record has demonstrated to potential partners that Eton can be an excellent partner for commercializing ultra-rare disease products in the United States. And our growing profitability has expanded our financial capacity, allowing us to pursue a broader range of transactions, including potentially larger opportunities. We remain incredibly excited about Eton's future. We believe we are still in the early stages of building the leading rare disease company in the United States and bringing as many important therapies as possible to patients with rare diseases while creating significant long-term value for our shareholders. With that, I'll turn it over to [ Judy Matthews ], our Chief Financial Officer, to discuss our financial results. [ Judy ]?

Unknown Executive

Thank you, Sean. Second quarter revenue increased 99% to $37.6 million compared to $18.9 million in the second quarter of 2025, driven by the addition of Hemangiol, as well as strong year-over-year growth from Increlex, [ Alcatraz ], and the U.S. Alkindi Sprinkle, [ KendiV ], Galzin, and carglumic acid. Gross profit for the quarter was $25.4 million compared to $11.9 million in the prior year period, an increase of 113%, primarily driven by higher product sales. Adjusted gross profit, which excludes the impact of acquired inventory step-up adjustments and intangible amortization, was $27.4 million in the second quarter of 2026, representing an adjusted gross margin of 73%. This compares to adjusted gross profit of $14.1 million and adjusted gross margin of 75% in the prior year period. The decrease in adjusted gross margin was primarily attributable to higher Increlex sales outside the U.S., which generate a negative gross margin.

We expect full-year adjusted gross margin to exceed 70%, inclusive of a potential commercial milestone expected to be recorded in the fourth quarter of 2026 upon achievement of certain net sales thresholds for Alkindi Sprinkle and [ KendiV ]. R&D expenses for the quarter were $1 million compared to $3.7 million in the prior year period. The decrease was primarily due to the [ Desmoda ] FDA filing fee incurred in 2025. We expect full year R&D spending to be between $10 million and $14 million, including the $3 million upfront licensing payment for ASN001, which we expect to expense as R&D in the third quarter of 2026. General and administrative expenses for the quarter were $11.6 million compared to $9.7 million in the prior year period, an increase of 20%. On an adjusted basis, which excludes the impact of share-based compensation, transaction-related costs, and other one-time expenses, G&A expense was $10.2 million compared to $7.6 million in the prior year period.

The increase was primarily driven by additional headcount to support the growth of our business with FDA fees accounting for $0.9 million of the year-over-year increase. Adjusted EBITDA for the second quarter of 2026 was $16.2 million or 43% of revenue compared to $3.1 million or 16% of revenue in the prior year period. We expect our full-year adjusted EBITDA margin to exceed 35%, even after the potential commercial milestone referenced above and R&D expenses related to the ASN001 licensing payment and bioavailability study. Total company net income was $11.6 million or $0.35 per diluted share compared to a net loss of $2.6 million or $0.10 per basic and diluted share in the prior year period. On a non-GAAP basis, we reported net income of $14.3 million for the second quarter of 2026 compared to $1.5 million in the prior year period. Diluted earnings per share were $0.43 compared to $0.03 per share in the prior year period.

Through the second quarter of 2026, we maintained a full valuation allowance against our net deferred tax assets. While our operating results have improved significantly, we remained in a cumulative loss position at quarter end for purposes of our valuation allowance assessment. If we continue to execute against our current forecast and exit this cumulative loss position during the second half of 2026, we may determine that some or all of the valuation allowance is no longer necessary. As of June 30, 2026, our valuation allowance was approximately $22 million. If the valuation allowance is released in a future period, the release would result in a significant one-time non-cash income tax benefit and a corresponding increase in reported GAAP net income in the period in which it is recorded.

We ended the second quarter with $26.8 million in cash on hand after making a $3 million prepayment on our outstanding debt. We remain in a strong financial position and expect cash generated from operations to grow throughout the second half of the year. We will continue to prioritize the use of our cash reserves to fund accretive product acquisitions while accelerating the repayment of our remaining credit facility over the next 6 to 12 months. This concludes our remarks on second quarter results. With that, we'll turn the call back over to the operator for Q&A.

Operator

[Operator Instructions] Our first question comes from Chase Knickerbocker with Craig-Hallam Capital Group. Your line is open.

分析师问答

Chase Knickerbocker

Maybe just first from me on Hemangiol. Can you give us a sense for what the net realized price is in the quarter now that we have a couple months under our belt? How does that compare to the previous quarter, to the kind of $8,000 to $10,000 per treated patient for a full course of therapy that you had kind of previously expected? And if you could give us a sense for volume, we had a sense for kind of the patients that were on drug prior to the purchase. Is that pretty comparable in 95% of kind of the patients who were on prior were retained and, you know, we should be thinking about that volume kind of going forward?

David Krempa

Chase, on the net pricing, we're still sticking with that $8,000 to $10,000 net price. On average, we think that's going to be our best estimate. It moves around month to month, especially during this transition based on patient mix, but we still think it'll be more or less in that $8,000 to $10,000 range. In terms of patient volume, yes, historically there's been 8,000 patients. We think we've converted all the patients now. We had 95% by end of June. We think we've got them all now. Now the commercial team's focus is on trying to grow that volume and convert some of the patients that historically have used the off-label adult product. So that'll be the game plan going forward.

Chase Knickerbocker

Got it. Maybe just to follow up there, there's kind of a 6 months turnover, obviously, in these patients as they roll off therapy. Can you just speak to kind of the efforts on getting in front of all of those providers now that the Hemangiol is under Eton ownership and kind of the success of kind of how many of those physicians, those writers that you've, you know, have been able to get in front of and kind of capture scripts subsequent to the change in ownership? And then second, just on ASN001, could you just outline exactly the FDA feedback that your partner got around the bioavailability bridging study? Is that what's going to be considered the registrational study by FDA? Or are they taking that clinical study in China into consideration as supportive evidence?

Sean Brynjolfsson

Hi, Chase. I'll take that last question you have, and then Ipek can take the first part. So, for ASN001, this is the only study we need to run before we file it. The rest of the dossier is largely complete. This is, you can think of it almost as a bio, it's not exactly a bioequivalency study. It's a demonstration that our product has absorption characteristics similar to a comparator product that's in the market today, and that basically demonstrating that the absorption and metabolism of the molecule for the body is similar. We view it as very straightforward and low-risk. We're highly confident that we will be filing that product middle of next year. And as we said in our earlier communications, we believe that product will be a very large product for the company, likely its largest product.

Ipek Erincin

Thank you for the first part of your question on Hemangiol. Things to note there for the kind of.

Operator

Ladies and gentlemen, please stand by. Gary, please repeat the question.

Unknown Analyst

Hey guys, this is [ Dennis Resnick ], on for Gary Nachman. So just starting with the recent acquisition of ASN001, can you just talk a little bit more about the synergies you expect to leverage with the Hemangiol franchise and how much of the infrastructure there could help out once this product is approved? And then on the recent acquisition of Impavido. The product's been available since 2016, so maybe just talk about what you already know about the market and then what you plan to do differently to ensure commercialization and growth and how big this product can get. And I've got 1 follow-up.

Sean Brynjolfsson

Sure. So on ASN001, we're very excited about the product. We believe we'll file it in the middle of next year. It'll leverage our existing hemangioma sales team. We think this product is an ideal fit for the company. It's also a demonstration of our commitment to really supporting the hemangioma community. And the product is expected to be our largest revenue generating product when we launch it, likely in 2028. Regarding Impavido, Ipek, why don't you take that one?

Ipek Erincin

Sure. So I think if you look at the previous commercialization before our time, before our acquisition, it was basically distributed by a single person distributor structure. So there was no field sales force on the ground actually talking to these infectious disease experts and specialists. So there are many levers that we are going to pull. Also, it wasn't covered traditionally by Medicaid. The distribution was quite dispersed in the sense that it was relatively difficult for patients to figure out what pharmacy to get the product. There was obviously not a copay support in place. So we think that we are going to pull many of those levers and really bring meaningful value to both the prescribers and the patients.

It's obvious, we already know the targets. It's a very nice fit in terms of a very concentrated target space. It's going to be around 300 clients. Salesforce targets were very much in a concentrated capacity that managed the leishmaniasis. So we are pretty confident that with our Salesforce, specialist Salesforce, we are going to get to those infectious disease specialists. Obviously, the guidelines and the therapy profile supports as it is the only FDA-approved product for the therapy. And then we are putting it into our Eton Cares model where these providers and patients will know where to get the product, get the $0 copay support. We are obviously going to be able to cover the Medicaid patients that actually need the government coverage and hopefully we'll be in a much better place in terms of the patient and provider experience.

Unknown Analyst

That's super helpful. And then just on the quarterly results, I mean just any more color you can give about how much upside Hemangiol, about how much the Hemangiol launch provided this quarter and how should we be thinking about sequential growth for that product moving forward? And then any color you can give about how the launch of [ Desmoda ] helped in this quarter particularly? And that's the rest of my questions.

Sean Brynjolfsson

Sure, so we're not going to give product-specific guidance as we haven't done that in the past, but I can tell you that we believe there's significant growth opportunity on Hemangiol. This is 1 where the patient support and the Eton Cares service adds a lot of value that wasn't there previously. And also, obviously, with the much lower copay, we think that patients will be less likely to use off-label product and will stay on Hemangiol as well as be prescribed it to a greater extent. Ultimately, the annual patients should be exceeding 10,000 a year.

Unknown Executive

And regarding your question about the [ Desmoda ] impact, you know, launch is going well, but from a financial standpoint, it was only its first full quarter on the market. So it wasn't a huge contributor to the growth that you saw in Q2, but as we exit this year, we expect to start seeing a meaningful contribution from that product that will drive our long-term growth as we get to some of those peak sales numbers we talked about for the product.

Operator

Our next question comes from [ Madison El-Saadi ] with B. Riley Securities. Your line is open. Madison, if you're muted, please unmute.

Unknown Analyst

So it sounds like much of the Q2 beat here came from Hemangiol. How much of the $25 million raised guide is Hemangiol versus everything else?

Sean Brynjolfsson

So, thanks for the question, Madison. As I said previously to a similar question, we're not going to break out our products, as we generally haven't done that in the past. And I think that from a go-forward standpoint, I can say that we expect Hemangiol to continue to grow. As was indicated, we've largely completed all the conversions from, you know, the old pharmacies to the new pharmacy system. And so that the patient conversion process is complete. We're now looking to grow that business and it is growing. It actually, we're really encouraged by the product. We think it still has a lot of runway. And more importantly, we're super excited about ASN001, a late-stage product that will fit in perfectly with our pediatric dermatology sales team. And that's a product that's been a patient request and a doctor request for a long time that will certainly fit well and we hope to launch that in the next whatever 12 to 20 months.

Unknown Analyst

Got it. If I may, a quick follow-up. As you're thinking on [ Desmoda ] peak opportunity, has that changed? And now, you know, your sales team, you know, [ KendiV ], Increlex, multiple, you know, options in the bag here. I guess at what point does the team need to get bigger?

Ipek Erincin

Thank you, Madison. I think in terms of the [ Desmoda ] peak opportunity at this point, we'll keep it the same with our guidance from the past. So I think we said around 40 to 50 as our peak number. So we will still keep it at the same. It's been a very encouraging first 5 months. Actually, in terms of the patient ads, we are over, like we are around 115% of targets. But from a, again, how fast we are going to get there, it's too early to tell, but the clinician feedback and current patient build has been very much encouraging. So, but we'll keep our guidance and the apportion to the peak size the same.

In terms of the Salesforce size, I think at this point, the Alkindi and [ KendiV ] being basically an adrenal insufficiency franchise, so they are really addressing the same conditions. So we are approaching that as a portfolio sell. Increlex, as you know, is a very much ultra-rare specialty cells. And the great thing here is when you look at the prescribers, obviously they're all endocrinologists, but there's also a very strong over 90% overlap, even though some endocrinologists are specialists in certain diseases. So I think at this point, we are not planning any expansion of the sales force. We think that our infrastructure is pretty much, you know, sufficient and effective for the current portfolio.

Operator

Our next question comes from RK with H.C. Wainwright. Your line is open.

RK

In general, it's just trying to understand how you plan on having ASN001 and Hemangiol work out that franchise, especially with Hemangiol patent running out in October '28, I believe. Is there any way for you to extend that or is ASN001 the answer for that?

Sean Brynjolfsson

So thank you for the question. Okay, the Hemangiol formulation, I would say, has some aspects which can be improved, and so we're looking at some formulation improvements, which we think will be better for the patients and certainly for the caregivers. We'll get into that a little later. So there is an opportunity there to add some IP in addition. I would say that for ASN001, that has a very obviously long runway in terms of patent protection. That market is several orders larger than Hemangiol. I'd say that, you know, look at Hemangiol as something that is used to treat the severe hemangiomas and ASN001 will have 20,000 to 30,000, we believe at a minimum, number of patients. There actually is, you know, 200, FDA believes there's more than 200,000 patients that have hemangiomas in the United States. But we're giving it a nice haircut to make sure that, you know, we're giving it as accurate guidance as we can. But we believe, you know, the number could be significant. So that will certainly be a large product for us.

And, you know, we'll continue to do M&A and licensing and expand our pediatric dermatology franchise. When we get into a given therapeutic area, we continue to invest in it. For us, it's all about the patients. It's about building upon the treatment areas that we get involved in. It's not a 1 product kind of deal. We want to continue to build upon that.

RK

Thanks for that. Then on the Hemangiol itself, in terms of the patient economics, you know, you have 8,000 inherited patients, but at this point, how many are paying versus free drug program? And in terms of new patient acquisition rate, you know, where are you now since you started in May? And by the end of 2026, where do you think, you know, realistically could be the paying patient number?

Unknown Executive

All right, okay, we're not going to get into the specific breakdown of the payer mix for each patient, but we've said it's more or less coming in as we expected when we put out that $8,000 to $10,000 net number. So it's more or less in the ballpark. Obviously, it jumps around a little bit month to month and the first month or 2 with some transitions and some bridge product, but it should stabilize here as we go forward.

RK

Okay, let me try on Impavido. On that molecule, you know, you have a 50% to 55% of net sales going to Knight. So how much contribution does it do for your EBITDA line and how much of the demand is there that you're actually handling at this point?

Unknown Executive

So we're launching the product end of September, so no financial impact yet, but... Although there's a larger profit share, it was a little bit of a unique model. We paid very little up front, so we think it's still going to be a very attractive deal for the company. We think it can contribute multiple millions of dollars annually with very little up front, very little resource distraction, and good complementary fit with the rare disease strategy and the Eton Cares program. So it will be lower margin than some of our other products, but we think it'll still be an attractive opportunity and a very attractive return on investment relative to what we put up to get the distribution rights.

Operator

This concludes the question and answer session. You may now disconnect. Good day.